A citation-based method for searching scientific literature

Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
Times Cited: 6







List of co-cited articles
57 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
226
83

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
66

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
66

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
113
66

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
139
66

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
50

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
93
50

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
304
50



SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
23
50

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P McCarthy, Arman Qamar, James L Januzzi, Benjamin M Scirica, Javed Butler, Christopher P Cannon, Deepak L Bhatt. J Am Coll Cardiol 2018
75
33

Clopidogrel with or without omeprazole in coronary artery disease.
Deepak L Bhatt, Byron L Cryer, Charles F Contant, Marc Cohen, Angel Lanas, Thomas J Schnitzer, Thomas L Shook, Pablo Lapuerta, Mark A Goldsmith, Loren Laine,[...]. N Engl J Med 2010
796
33

Standardized rates of recurrent outcomes.
T A Stukel, R J Glynn, E S Fisher, S M Sharp, G Lu-Yao, J E Wennberg. Stat Med 1994
48
33

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
Deepak L Bhatt, Kim A Eagle, E Magnus Ohman, Alan T Hirsch, Shinya Goto, Elizabeth M Mahoney, Peter W F Wilson, Mark J Alberts, Ralph D'Agostino, Chiau-Suong Liau,[...]. JAMA 2010
513
33

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
435
33

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.
Subodh Verma, C David Mazer, Deepak L Bhatt, Satish R Raj, Andrew T Yan, Atul Verma, Ele Ferrannini, Gudrun Simons, Jisoo Lee, Bernard Zinman,[...]. Diabetes Care 2019
20
33

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
33

The COVID-19 pandemic: a catalyst to improve clinical trials.
Prakriti Gaba, Deepak L Bhatt. Nat Rev Cardiol 2020
27
33

The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19.
Senthil Selvaraj, Stephen J Greene, Sameed Ahmed M Khatana, Ashwin S Nathan, Scott D Solomon, Deepak L Bhatt. J Am Heart Assoc 2020
12
33

One-year cardiovascular event rates in outpatients with atherothrombosis.
Ph Gabriel Steg, Deepak L Bhatt, Peter W F Wilson, Ralph D'Agostino, E Magnus Ohman, Joachim Röther, Chiau-Suong Liau, Alan T Hirsch, Jean-Louis Mas, Yasuo Ikeda,[...]. JAMA 2007
939
33

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, Itamar Raz, Matthew A Cavender, KyungAh Im, Ofri Mosenzon, Jacob A Udell, Boaz Hirshberg, Pia S Pollack,[...]. JAMA Cardiol 2016
58
33

Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
Naresh Kumar, Ankit Garg, Deepak L Bhatt, Sandra Sabongui, Naveen Gupta, Sundeep Chaudhry, Ross Arena, Subodh Verma. Can J Physiol Pharmacol 2018
16
33

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
Jacob A Udell, Matthew A Cavender, Deepak L Bhatt, Saurav Chatterjee, Michael E Farkouh, Benjamin M Scirica. Lancet Diabetes Endocrinol 2015
187
33

Modeling marginal features in studies of recurrent events in the presence of a terminal event.
Per Kragh Andersen, Jules Angst, Henrik Ravn. Lifetime Data Anal 2019
12
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
517
33

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia.
Stephen E Sherman, Gillian I Bell, Hwee Teoh, Mohammed Al-Omran, Kim A Connelly, Deepak L Bhatt, David A Hess, Subodh Verma. JACC Basic Transl Sci 2018
19
33

Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk.
Sara B Seidelmann, Elena Feofanova, Bing Yu, Nora Franceschini, Brian Claggett, Mikko Kuokkanen, Hannu Puolijoki, Tapani Ebeling, Markus Perola, Veikko Salomaa,[...]. J Am Coll Cardiol 2018
34
33

Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials.
Mario Gaudino, Varun Arvind, Irbaz Hameed, Antonino Di Franco, Cristiano Spadaccio, Deepak L Bhatt, Emilia Bagiella. J Am Coll Cardiol 2020
10
33

Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
Tannas Jatene, Robert A Harrington, Gregg W Stone, Ph Gabriel Steg, C Michael Gibson, Christian W Hamm, Matthew J Price, Jayne Prats, Efthymios N Deliargyris, Kenneth W Mahaffey,[...]. J Am Coll Cardiol 2016
20
33

The Consequences of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials.
Emilia Bagiella, Deepak L Bhatt, Mario Gaudino. J Am Coll Cardiol 2020
26
33

The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
Erika Opingari, Subodh Verma, Kim A Connelly, Cyril David Mazer, Hwee Teoh, Adrian Quan, Fei Zuo, Yi Pan, Deepak L Bhatt, Bernard Zinman,[...]. Nephrol Dial Transplant 2020
16
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
33

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Deepak L Bhatt, Subodh Verma, Eugene Braunwald. Cell Metab 2019
20
33

Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Kim A Connelly, Deepak L Bhatt, Subodh Verma. Cell Metab 2018
16
33

SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
David A Hess, Daniella C Terenzi, Justin Z Trac, Adrian Quan, Tamique Mason, Mohammed Al-Omran, Deepak L Bhatt, Natasha Dhingra, Ori D Rotstein, Lawrence A Leiter,[...]. Cell Metab 2019
48
33

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Matthew A Cavender, Ph Gabriel Steg, Sidney C Smith, Kim Eagle, E Magnus Ohman, Shinya Goto, Julia Kuder, Kyungah Im, Peter W F Wilson, Deepak L Bhatt. Circulation 2015
290
33

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
Deepak L Bhatt, P Gabriel Steg, E Magnus Ohman, Alan T Hirsch, Yasuo Ikeda, Jean-Louis Mas, Shinya Goto, Chiau-Suong Liau, Alain J Richard, Joachim Röther,[...]. JAMA 2006
33

More CREDENCE for SGLT2 Inhibition.
Subodh Verma, Deepak L Bhatt. Circulation 2019
10
33

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
246
33

Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study.
Benoît Tyl, José Lopez Sendon, Jeffrey S Borer, Esteban Lopez De Sa, Guy Lerebours, Claire Varin, Aurélie De Montigny, Matthieu Pannaux, Michel Komajda. Circ Heart Fail 2020
13
33

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Biswajit Chowdhury, Albert Z Luu, Vincent Z Luu, M Golam Kabir, Yi Pan, Hwee Teoh, Adrian Quan, Sandra Sabongui, Mohammed Al-Omran, Deepak L Bhatt,[...]. Biochem Biophys Res Commun 2020
37
33

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
12
33


Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
9
33

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
10
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.